

**Regd. Office :-**  
330, TRIVIA Complex, Natubhai Circle,  
Racecourse, Vadodara – 390007, Gujarat, INDIA  
Phone : +91 265 2988903 / 2984803  
Website : www.chemcrux.com  
Email : girishshah@chemcrux.com



**CHEMCRUX**  
**ENTERPRISES LTD.**  
ISO 9001, 14001 & 50001 Certified Company  
CIN : L01110GJ1996PLC029329

To  
BSE LIMITED  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400 001

14<sup>th</sup> May 2026

Dear Sir/Madam

**Subject:** Audited Standalone & Consolidated Financial Statements & Results for the Quarter and Year ended 31<sup>st</sup> March 2026

**Ref: BSE Scrip ID:** CHEMCRUX      **BSE Scrip Code:** 540395

We would like to inform that the Board of Directors in its meeting held today i.e., Thursday, 14<sup>th</sup> May 2026 inter alia, considered and approved the Audited Standalone & Consolidated Financial Statements & Results for the quarter and year ended 31<sup>st</sup> March 2026 as recommended by the Audit Committee. The Board also recommended Final Dividend for F.Y. 2025-26 at the rate of 10% (Re. 1/- per share) on the Equity share of Rs. 10/- each subject to the approval of shareholders in the ensuing Annual General Meeting.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the herewith copy of the Audited Financial Results (Standalone and Consolidated) for the quarter & year ended 31<sup>st</sup> March 2026 along with the Auditor's Report issued by the Statutory Auditors of the Company. Further, declaration as to unmodified opinion of Auditors on the Audited Financial Statements & Results is also attached.

Kindly take above as compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11.30 A.M. and concluded at 04:10 P.M.

Thanking you

**For CHEMCRUX ENTERPRISES LIMITED**

**Dipika Rajpal**  
**Company Secretary & Compliance Officer**

### INDEPENDENT AUDITOR'S REPORT

Independent Auditors Report on the Standalone Annual Financial Results of M/s Chemcrux Enterprises Limited for the quarter and year ended on 31<sup>st</sup> March, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation, 2015.

TO  
THE BOARD OF DIRECTORS  
CHEMCRUX ENTERPRISES LIMITED  
Vadodara

### Report on the Audit of the Standalone Financial Results

#### Opinion

We have audited the accompanying Standalone Financial Results (the "Statement") of Chemcrux Enterprises Limited (the "Company") for the quarter and year ended March 31, 2026 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the Statement :

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended on March 31, 2026

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial results.



### **Management's Responsibilities for the Standalone Financial Results**

These standalone financial results have been prepared on the basis of the standalone financial statements. The Company's Management and Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors' are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.



We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



## Other Matters

The Standalone Financial Results include the results for the quarter ended March 31, 2026 and 31<sup>st</sup> March, 2025 being the balancing figures between the audited figures in respect of the full financial year ended 31<sup>st</sup> March, 2026 and 31<sup>st</sup> March, 2025 respectively and the published unaudited year to date figures up to the third quarter of the respective financial year which were subjected to a limited review by us as required under the Listing Regulations.

Our Opinion is not modified in respect of the above Other Matters

For Naresh & Co  
Chartered Accountants  
FRN: 106928W

  
CA Harin Parikh  
Partner



M.No. 107606

UDIN: 26107606NXQCUL8675

Place: Vadodara


Date: 14<sup>th</sup> May, 2026

**CHEMCRUX ENTERPRISES LIMITED**  
**STANDALONE BALANCE SHEET AS AT 31ST MARCH, 2026**

(Figures in Rs Lacs)

	Particulars	As at 31st March, 2026	As at 31st March, 2025
I.	<b>ASSETS</b>		
(1)	<b>Non - Current Assets</b>		
	(a) Property, Plant and Equipment	5,525.55	5,639.86
	(b) Capital Work In Progress	407.98	161.08
	(c) Investment Property	67.78	67.78
	(d) Right of Use Assets	22.12	44.23
	(e) Other Intangible Assets	2.67	2.84
	(f) Financial Assets		
	(i) Investments	5.70	5.70
	(ii) Loans	869.12	559.00
	(iii) Others	340.78	275.47
	(g) Other Non - Current Assets	-	-
(2)	<b>Current Assets</b>		
	(a) Inventories	602.96	964.89
	(b) Financial Assets		
	(i) Investments	1,588.29	1,978.15
	(ii) Trade Receivables	1,924.90	1,221.30
	(iii) Cash and Cash Equivalents	243.17	101.38
	(iv) Other Bank Balances	13.05	12.88
	(v) Loans	19.84	23.48
	(vi) Others	6.40	6.21
	(c) Other Current Assets	128.99	150.28
	<b>Total Assets</b>	<b>11,769.30</b>	<b>11,214.51</b>
II.	<b>EQUITY AND LIABILITIES</b>		
(1)	<b>Equity</b>		
	(a) Equity Share Capital	1,480.88	1,480.88
	(b) Other Equity	6,525.05	6,130.30
	<b>Liabilities</b>		
(2)	<b>Non - Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Long Term Borrowings	1,324.73	1,787.74
	(ii) Lease Liabilities	31.52	60.70
	(iii) Other Financial Liabilities	-	-
	(b) Provisions	-	-
	(c) Deferred Tax Liability (net)	402.97	346.46
(3)	<b>Current Liabilities</b>		
	(a) Financial liabilities		
	(i) Short Term Borrowings	846.95	816.02
	(ii) Lease Liabilities	17.95	16.54
	(iii) Trade Payables		
	a) Total Outstanding Dues of Micro Enterprises and Small Enterprises	85.10	26.44
	b) Total Outstanding Dues of Creditors Others than Micro Enterprises and Small Enterprises	805.76	374.66
	(iv) Other Financial Liabilities	54.22	60.42
	(c) Other Current Liabilities	175.12	108.77
	(b) Provisions	19.05	5.57
	(d) Current Tax Liabilities (Net)	-	-
	<b>Total Equity and Liabilities</b>	<b>11,769.30</b>	<b>11,214.51</b>

For & on behalf of the Board  
Chemcrux Enterprises Limited

  
Girish Kumar Shah  
Whole Time Director  
DIN : 00469291



Place : Vadodara  
Date : 14th May, 2026

**CHEMCRUX ENTERPRISES LIMITED**

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

**AUDITED STANDALONE STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2026**

(All amounts are in INR lacs, unless otherwise stated)

	Particulars	Quarter Ended			Year ended	
		31-03-2026 Audited	31-12-2025 Unaudited	31-03-2025 Audited	31-03-2026 Audited	31-03-2025 Audited
I.	Revenue from operations	2,428.14	2,299.74	1,596.56	8,257.92	7,025.39
II.	Other income	52.78	74.04	27.74	267.33	152.96
III.	<b>Total Income ( I+II)</b>	<b>2,480.92</b>	<b>2,373.77</b>	<b>1,624.30</b>	<b>8,525.25</b>	<b>7,178.35</b>
IV.	<b>Expenses:</b>					
	Cost of materials consumed	896.67	1,057.60	733.32	3,264.65	3,042.21
	Purchase of Traded Goods			-		-
	Changes in inventories of finished goods, by-products and work in progress	25.53	(118.40)	(187.64)	421.50	(236.26)
	Employee benefits expense	248.37	246.05	218.59	907.64	852.68
	Finance costs	40.48	45.61	58.29	190.53	163.84
	Depreciation and amortization expense	94.49	95.34	91.46	380.75	313.06
	Other expenses	894.64	778.74	637.47	2,639.28	2,460.01
	<b>Total expenses (IV)</b>	<b>2,200.19</b>	<b>2,104.93</b>	<b>1,551.50</b>	<b>7,804.36</b>	<b>6,595.54</b>
V.	<b>Profit Before Tax</b>	<b>280.73</b>	<b>268.84</b>	<b>72.79</b>	<b>720.89</b>	<b>582.81</b>
VIII.	<b>Tax expense :</b>					
	Current tax	62.88	49.50	2.66	122.00	75.00
	Deferred tax	19.17	14.74	22.62	57.23	90.06
	Income tax relating to earlier years	-	(3.30)	0.07	(3.30)	(1.11)
		<b>82.05</b>	<b>60.94</b>	<b>25.35</b>	<b>175.92</b>	<b>163.96</b>
IX.	<b>Profit for the period</b>	<b>198.68</b>	<b>207.90</b>	<b>47.45</b>	<b>544.97</b>	<b>418.86</b>
X.	<b>Other comprehensive income</b>					
	(i) Items that will not be reclassified to profit or loss					
	- Defined Benefit Plan	9.68	2.40	18.88	(1.56)	26.18
	(ii) Income tax relating to items that will not be reclassified to profit or loss	2.44	0.60	4.75	(0.39)	6.59
	(iii) Items that will be reclassified to profit or loss					
	-Fair Value Gain on Investments	19.62	23.75	39.91	110.14	126.92
	(iv) Income tax relating to items that will be reclassified to profit or loss	4.94	5.98	10.04	27.72	31.95
	<b>Total other comprehensive income, net of tax</b>	<b>21.93</b>	<b>19.56</b>	<b>43.99</b>	<b>81.25</b>	<b>114.57</b>
XI.	<b>Total comprehensive income for the period</b>	<b>220.61</b>	<b>227.46</b>	<b>91.44</b>	<b>626.22</b>	<b>533.42</b>
	<b>Paid Up Equity Share Capital (face value of Rs. 10/- each)</b>				<b>1,480.88</b>	<b>1,480.88</b>
	<b>Other Equity</b>				<b>6,525.82</b>	<b>6,130.30</b>
XII.	<b>Earnings per equity share (Nominal value per share Rs. 10/-)</b>					
	- Basic (Rs.)	<b>1.34</b>	<b>1.40</b>	<b>0.32</b>	<b>3.68</b>	<b>2.83</b>
	- Diluted (Rs.)	<b>1.34</b>	<b>1.40</b>	<b>0.32</b>	<b>3.68</b>	<b>2.83</b>




**Notes to Standalone Financial Results :**

- 1 The above financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other
- 2 The above financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 14th May, 2026.
- 3 The above financial results have been audited by the Statutory Auditors as required under Regulation 33 and Regulation 52 of the SEBI (LODR) Regulations, 2015 as amended.
- 4 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of ind AS 108, on Operating Segment, constitute a single operating segment.
- 5 The Board of Directors of the Company at its Board Meeting held on 14h May 2026, recommended a dividend @10% (i.e. Re. 1/- per share of FV Rs. 10/- each) as Final Dividend for the year ended on 31st March 2026, subject to the approval of the same by the shareholders in the ensuing annual general meeting.
- 6 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Codes viz Code on Wages 2019, Code on Social Security 2020, Industrial Relation Code 2020 and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from 21 November, 2025.

The Company has estimated and accounted liability related to gratuity and leave encashment in the standalone financial results and expense for which is included in employee benefits expense. The Company continues to monitor developments on the rules to be notified by regulatory authorities, including clarifications / additional guidance from authorities and will continue to assess the accounting implications, basis such developments/ guidance.

- 7 The figures of the quarter ended 31st March, 2026 and 31st March, 2025 represent the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the respective financial year which were subject to limited review by the Statutory Auditors as required under the Listing Regulations.
- 8 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

**For & on behalf of the Board  
Chemcrux Enterprises Limited**

  
Girishkumar Shah  
Whole Time Director  
DIN : 00469291




Place : Vadodara  
Date : 14th May, 2026

**CHEMCRUX ENTERPRISES LIMITED**  
**STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2026**

(Figures in Rs Lacs)

Sr.	Particulars	Year ended 31st March , 2026	Year ended 31st March , 2025
<b>A.</b>	<b>Cash flow from Operating Activities :</b>		
	<i>Net Profit before Tax &amp; Extra Ordinary Items</i>	720.89	582.81
	Adjustment for :		
	Depreciation & Write-offs	380.75	313.06
	Loss/(Profit) on Sale of PPE	-	(5.98)
	Interest Expense	190.53	163.84
	Interest Income	(79.56)	(74.67)
	Provision for Expected Credit Loss	2.13	-
	Gain on Mutual Funds	(111.44)	(23.81)
	Gratuity Expense	13.92	14.20
	<b>Operating Profit before Working Capital Changes</b>	<b>1,117.22</b>	<b>969.45</b>
	Adjustments for :		
	(Increase)/Decrease in Trade Receivables	(705.74)	308.69
	(Increase)/Decrease in Inventories	361.93	(123.83)
	(Increase)/Decrease in Loans & Advances	3.45	(0.49)
	(Increase)/Decrease in other current assets	40.64	4.71
	Increase/(Decrease) in Trade Payable	489.76	(196.91)
	Increase/(Decrease) in Other Current Liabilities	46.56	(112.98)
	Increase/(Decrease) in Short Term Provisions	(2.00)	-
	<b>Cash Generated from Operating Activities</b>	<b>1,351.82</b>	<b>848.64</b>
	Direct Taxes Paid	(131.65)	(141.82)
	<i>Cash Flow before Extra Ordinary Items</i>	1,220.17	706.82
	Prior Period Items ( being cash items )	-	-
	<b>Net Cash Flow from Operating Activities</b>	<b>1,220.17</b>	<b>706.82</b>
<b>B.</b>	<b>Cash Flow from Investing Activities</b>		
	Purchase of PPE	(495.17)	(825.35)
	Net Proceeds from Sale of PPE	4.09	17.00
	Dividend Received	-	-
	Investments (Net)	500.00	149.48
	Loan Given to Related Parties	(310.12)	(209.00)
	Interest Received	73.16	74.67
	<b>Net Cash used in Investment Activities</b>	<b>(228.03)</b>	<b>(793.21)</b>
<b>C.</b>	<b>Cash Flow from Financing Activities</b>		
	Interest Paid	(176.93)	(163.84)
	(Increase)/Decrease in Financial and Other - Non Current Assets	(65.31)	(41.43)
	Increase/(Decrease) in Short Term Borrowings	30.93	414.06
	Increase/(Decrease) in Lease Liabilities	(27.77)	(13.35)
	Increase/(Decrease) in Long Term Borrowings	(463.01)	(364.94)
	Dividend Paid	(148.09)	(148.09)
	<b>Net Cash used in Financing Activities</b>	<b>(850.18)</b>	<b>(317.59)</b>
<b>D.</b>	<b>Net Increase/(Decrease) in Cash and Bank Balance</b>	<b>141.95</b>	<b>(403.97)</b>
	<b>Cash &amp; Bank Balance at beginning of the year</b>	<b>114.26</b>	<b>518.24</b>
	<b>Cash &amp; Bank balances at the end of the year</b>	<b>256.22</b>	<b>114.26</b>
	<b>Details of Cash &amp; Bank Balance</b>		
	Balances with Banks	240.43	99.75
	Cash on hand	3.25	1.97
	Deposits held as Margin Money	12.54	12.54
	Other Fixed Deposits with Bank	-	-

For & on behalf of the Board  
Chemcrux Enterprises Limited

  
Girish Kumar Shah  
Whole Time Director  
DIN : 00469291



Place : Vadodara  
Date : 14th May, 2026

Regd. Office :-  
330, TRIVIA Complex, Natubhai Circle,  
Racecourse, Vadodara – 390007, Gujarat, INDIA  
Phone : +91 265 2988903 / 2984803  
Website : www.chemcrux.com  
Email : girishshah@chemcrux.com



14<sup>th</sup> May 2026

To  
BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400 001

Dear Sir/Madam,

**Subject:** Declaration in respect of unmodified opinion on Audited Standalone Financial Statements & Results for the Financial Year ended 31<sup>st</sup> March 2026.

**Ref.:** BSE Scrip ID: **CHEMCRUX** BSE Scrip Code: **540395**

In terms of Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; I, Girishkumar Shah, Whole-time Director of Chemcrux Enterprises Limited, hereby declare that the Statutory Auditors of the Company viz. M/s Naresh & Co., Chartered Accountants (FRN 106928W); have issued Audit Report dated 14<sup>th</sup> May 2026 with unmodified opinion on the Annual Audited Standalone Financial Statements & Results for the financial year ended 31<sup>st</sup> March 2026.

Kindly take the above on your records.

**For CHEMCRUX ENTERPRISES LIMITED**

A handwritten signature in blue ink, appearing to read "Girishkumar Shah".



**Girishkumar Shah**  
Whole-time Director

**INDEPENDENT AUDITOR'S REPORT ON THE CONSOLIDATED FINANCIAL RESULTS OF CHEMCRIX ENTERPRISES LIMITED FOR THE QUARTER AND YEAR ENDED 31<sup>ST</sup> MARCH, 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

**To the Board of Directors of Chemcruz Enterprises Limited**

**Opinion**

We have audited the accompanying Consolidated Annual Financial Results ("the Statement") of Chemcruz Enterprises Limited ("the Holding Company") and its Subsidiary (Holding Company and its Subsidiary together referred to as "the Group") for the quarter and the year ended 31<sup>st</sup> March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('LODR Regulations')

In our opinion, and to the best of our information, and according to the explanations given to us and based on the consideration of our report on separate audited financial statements of subsidiary, the Statement :

(i) includes the annual financial results of the following entities :


Name of Subsidiary : Kalichem Private Limited

(ii) are presented in accordance with the requirements of Regulation 33 of the LODR Regulations as amended; and

(iii) give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for quarter and the year ended 31<sup>st</sup> March 2026.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.



### **Management's Responsibilities for the Consolidated Financial Results**

These Consolidated Financial Results have been prepared on the basis of the Consolidated Annual Financial Statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the Companies included in the Group responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the Companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls. The said section 143(3)(i) is not applicable to the Subsidiary Company, and accordingly, while we are the auditors for both the Holding and the Subsidiary Company, our opinion on internal financial controls is expressed only in respect of the Holding Company.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Holding Company and / or its Subsidiary to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Holding Company and / or its Subsidiary to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results of the Holding Company and its Subsidiary to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors.



For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

### Other Matters

- a) The Holding Company initially held 50% stake in Kalichem Private Limited making it a Joint Venture. The Holding Company acquired balance 50% stake in Kalichem Private Limited from the co-venturer M/s. Kalintis Healthcare Private Limited on 27th February, 2025. As a result of the acquisition, Kalichem Private Limited became a wholly-owned subsidiary of the Holding Company from that date.
- b) The Company has Consolidated the Financial Results of Kalichem Private Limited as a Joint Venture under the Equity Method in accordance with Ind AS 28 till 27th February, 2025 i.e. the date on which Kalichem Private Limited became a wholly-owned subsidiary. For the subsequent period, i.e. from 27th February, 2025 to 31st March, 2025 and for the Financial Year 2025-26, the Consolidation has been done as a Wholly Owned Subsidiary under Ind AS 110 following the principles of Ind AS 103 Business Combinations
- c) The Subsidiary Company had commenced commercial production on November 26, 2024. Prior to this date, all its operating expenses were capitalized to Property, Plant and Equipment, as pre-operative period, in accordance with Ind AS. Only post-commencement of commercial operations, these expenses are charged to the Statement of Profit and Loss. As a result, the operating expenses of Subsidiary included in the Consolidation for the year ended 31st March, 2025 only represent the post-capitalisation period i.e. November 26, 2024 to March 31, 2025 whereas those for the year ended 31st March, 2026 represent the full year.



- d) The Consolidated Financial Results include the results for the quarter ended 31<sup>st</sup> March 2026 and 31<sup>st</sup> March, 2025 being the balancing figure between the audited figures in respect of the full financial year and the year to date figures upto the third quarter of the respective financial year which were subject to limited review by the respective Statutory Auditors as required under the Listing Regulations

Our opinion on the consolidated Financial Results is not modified in respect of the above matters.

**For Naresh & Co**  
**Chartered Accountants**  
**FRN: 106928W**

  
CA Harin Parikh  
Partner



**M.No. 107606**  
**UDIN: 26107606XEEMJG6188**


**Place: Vadodara**  
**Date: 14<sup>th</sup> May, 2026**

**CHEMCRUX ENTERPRISES LIMITED**  
**CONSOLIDATED BALANCE SHEET AS AT 31ST MARCH, 2026**

(Figures in Rs Lacs)

	Particulars	Note No.	As at 31st March, 2026	As at 31st March, 2025
<b>I.</b>	<b>ASSETS</b>			
(1)	<b>Non - Current Assets</b>			
	(a) Property, Plant and Equipment	4	7,393.45	7,580.93
	(b) Capital Work In Progress	5	407.98	161.08
	(c) Investment Property	6	67.78	67.78
	(d) Right of Use Assets	7	22.12	44.23
	(e) Other Intangible Assets	8	12.67	12.84
	(f) Financial Assets			
	(i) Investments	9	4.70	4.70
	(ii) Loans	10	-	-
	(iii) Others	11	202.71	200.70
	(g) Other Non - Current Assets	12	-	-
(2)	<b>Current Assets</b>			
	(a) Inventories	13	610.66	1,001.66
	(b) Financial Assets			
	(i) Investments	9	1,588.29	1,978.15
	(ii) Trade Receivables	14	1,891.49	1,178.08
	(iii) Cash and Cash Equivalents	15	243.45	101.64
	(iv) Other Bank Balances	16	13.05	12.88
	(v) Loans	17	19.84	23.48
	(vi) Others	18	7.36	7.19
	(c) Other Current Assets	19	258.21	329.38
	<b>Total Assets</b>		<b>12,743.77</b>	<b>12,704.71</b>
<b>II.</b>	<b>EQUITY AND LIABILITIES</b>			
(1)	<b>Equity</b>			
	(a) Equity Share Capital	20	1,480.88	1,480.88
	(b) Other Equity	21	6,204.22	5,981.37
	<b>Liabilities</b>			
(2)	<b>Non - Current Liabilities</b>			
	(a) Financial Liabilities			
	(i) Long Term Borrowings	22	2,173.67	2,804.79
	(ii) Lease Liabilities	23	31.52	60.70
	(iii) Other Financial Liabilities	24	-	-
	(b) Provisions	25	-	5.57
	(c) Deferred Tax Liability (net)	26	402.97	367.25
(3)	<b>Current Liabilities</b>			
	(a) Financial liabilities			
	(i) Short Term Borrowings	27	1,213.77	1,348.00
	(ii) Lease Liabilities	23	17.95	16.54
	(iii) Trade Payables	28		
	a) Total Outstanding Dues of Micro Enterprises and Small Enterprises		92.27	45.02
	b) Total Outstanding Dues of Creditors Others than Micro Enterprises and Small Enterprises		836.91	403.53
	(iv) Other Financial Liabilities	24	81.23	72.55
	(c) Other Current Liabilities	29	189.32	118.50
	(b) Provisions	25	19.05	-
	(d) Current Tax Liabilities (Net)	30	-	-
	<b>Total Equity and Liabilities</b>		<b>12,743.77</b>	<b>12,704.71</b>

For & on behalf of the Board  
Chemcrux Enterprises Limited

  
Girishkumar Shah  
Whole Time Director  
DIN : 00469291



Place : Vadodara  
Date : 14th May, 2026

## CHEMCRUX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

AUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2026

(All amounts are in INR Lacs, Unless otherwise stated)


	Particulars	Quarter Ended			Year ended	
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
		Audited	Unaudited	Audited	Audited	Audited
I.	Revenue from operations	2,428.20	2,211.46	1,572.16	8,064.64	7,000.99
II.	Other income	35.69	60.23	23.52	202.49	148.74
III.	<b>Total Income ( I+II)</b>	<b>2,463.88</b>	<b>2,271.70</b>	<b>1,595.68</b>	<b>8,267.13</b>	<b>7,149.73</b>
IV.	<b>Expenses:</b>					
	Cost of materials consumed	898.09	839.47	669.64	2,832.61	2,978.53
	Purchase of Traded Goods	-	-	-	-	-
	Changes in inventories of finished goods, by-products and work in progress	25.53	(86.03)	(187.64)	421.50	(236.26)
	Employee benefits expense	263.00	261.91	222.35	963.12	856.44
	Finance costs	70.13	76.14	69.00	314.68	174.55
	Depreciation and amortization expense	117.37	118.68	98.96	473.31	320.56
	Other expenses	822.77	843.01	656.84	2,733.69	2,479.38
V.	<b>Total expenses (IV)</b>	<b>2,196.88</b>	<b>2,053.18</b>	<b>1,529.15</b>	<b>7,738.91</b>	<b>6,573.19</b>
VI.	<b>Profit Before Share in profit of Joint Venture (III-IV)</b>	<b>267.00</b>	<b>218.52</b>	<b>66.52</b>	<b>528.22</b>	<b>576.54</b>
VII.	<b>Share in Profit/(Loss) of Joint Venture (Net of Tax)</b>	-	-	-	-	(0.50)
VIII.	<b>Profit Before Tax</b>	<b>267.00</b>	<b>218.52</b>	<b>66.52</b>	<b>528.22</b>	<b>576.04</b>
IX.	<b>Tax expense :</b>					
	Current tax	62.88	49.50	2.66	122.00	75.00
	Deferred tax	19.17	14.74	43.41	36.44	110.85
	Income tax relating to earlier years	-	(3.30)	0.07	(3.30)	(1.11)
		<b>82.05</b>	<b>60.94</b>	<b>46.13</b>	<b>155.14</b>	<b>184.74</b>
X.	<b>Profit for the period</b>	<b>184.95</b>	<b>157.58</b>	<b>20.39</b>	<b>373.08</b>	<b>391.30</b>
XI.	<b>Other comprehensive income</b>					
	(i) Items that will not be reclassified to profit or loss					
	- Defined Benefit Plan	9.68	2.40	18.88	(1.56)	26.18
	(ii) Income tax relating to items that will not be reclassified to profit or loss	2.44	0.60	4.75	(0.39)	6.59
	(iii) Items that will be reclassified to profit or loss					
	-Fair Value Gain on Investments	19.62	23.75	39.91	110.14	126.92
	(iv) Income tax relating to items that will be reclassified to profit or loss	4.94	5.98	10.04	27.72	31.95
	<b>Total other comprehensive income, net of tax</b>	<b>21.93</b>	<b>19.56</b>	<b>43.99</b>	<b>81.25</b>	<b>114.57</b>
XII.	<b>Total comprehensive income for the period</b>	<b>206.88</b>	<b>177.14</b>	<b>64.39</b>	<b>454.33</b>	<b>505.87</b>
	<b>Profit for the period/year attributable to:</b>					
	Owners of the Company	184.95	157.58	20.39	373.08	391.30
	<b>Other comprehensive income for the period/year attributable to:</b>					
	Owners of the Company	21.93	19.56	43.99	81.25	114.57
	<b>Total comprehensive income for the period attributable to:</b>					
	Owners of the Company	206.88	177.14	64.39	454.33	505.87
	<b>Paid Up Equity Share Capital (face value of Rs. 10/- each)</b>				1,480.88	1,480.88
	<b>Other Equity</b>				6,205.01	5,981.37
XIII.	<b>Earnings per equity share (Nominal value per share Rs. 10/-)</b>					
	- Basic (Rs.)	1.25	1.06	0.14	2.52	2.64
	- Diluted (Rs.)	1.25	1.06	0.14	2.52	2.64


**Notes to Consolidated Financial Results :**

- 1 List of Entities Consolidated included in the  
**Kalichem Private Limited**  
Joint Venture till 26.02.2025  
Wholly-Owned Subsidiary from 27.02.2025
- 2 The above consolidated financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time
- 3 The above consolidated financial results have been reviewed by the Audit Committee and Approved by the Board of Directors in their respective Meetings held on 14th May, 2026
- 4 The above consolidated audited financial results have been audited by the Statutory Auditors as required under Regulation 33 and Regulation 52 of the SEBI (LODR) Regulations, 2015 as amended.
- 5 The Holding Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of in AS 108, on Operating Segment, constitute a single operating segment.
- 6 During the last quarter of the previous year, M/s. Chemcrux Enterprises Ltd which held 50% stake in Kalichem Private Limited the Company, acquired the balance 50% stake from the co-venturer Company M/s. Kalintis Healthcare Private Limited on 27th February, 2025. As a result of the acquisition, Kalichem Private Limited became a wholly-owned subsidiary of M/s. Chemcrux
- 7 The Company has Consolidated the Financial Results of Kalichem Private Limited as a Joint Venture under the Equity Method in accordance with Ind AS 28 till 27th February, 2025 i.e. the date on which Kalichem Private Limited became a wholly-owned subsidiary. For the subsequent period, i.e. from 27th February, 2025 to 31st March, 2025 & for the Financial Year 2025-26, the Consolidation has been done as a Wholly Owned Subsidiary under Ind AS 110 following the principles of Ind AS 103 Business
- 8 The Subsidiary Company commenced commercial production on November 26, 2024. Prior to this date, operating expenses were capitalized as Property, Plant and Equipment (CWIP) in accordance with Ind AS. Only post-commencement of commercial operations, these expenses are charged to the Statement of Profit and Loss. As a result, the operating expenses of Subsidiary included in the Consolidation for the year ended 31st March, 2025 only represent the post-capitalisation period whereas those for the year ended 31st March, 2026 represent the full year.
- 9 The Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Codes viz Code on Wages 2019, Code on Social Security 2020, Industrial Relation Code 2020 and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from 21 November, 2024.  
  
The Company has estimated and accounted liability related to gratuity and leave encashment in the standalone financial results and expense for which is included in employee benefits expense. The Company continues to monitor developments on the rules to be notified by regulatory authorities, including clarifications / additional guidance from authorities and will continue to assess the same
- 11 The Standalone Financial Results of Kalichem Private Limited for the quarter and year ended on 31st March, 2026 and 31st March, 2025 have been audited by the respective statutory auditors who have who have furnished their Unmodified Opinion on the same
- 12 The figures of the quarter ended March 31, 2026 and quarter ended March 31 2025 are the balancing figures between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the respective financial year which were subject to limited review by the respective Statutory Auditors as required under the Listing Regulations
- 13 The Board of Directors of the Holding Company at its Board Meeting held on 14th May 2026, recommended a dividend @ 10% (i.e. Rs.1/-per share of FV Rs. 10/- each) as Final Dividend for the year ended on 31st March 2026, subject to the approval of the same by the shareholders in the ensuing annual general meeting.
- 14 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

For & on behalf of the Board  
Chemcrux Enterprises Limited

  
Girishkumar Shah  
Whole Time Director  
DIN : 00469291




Place : Vadodara  
Date : 14th May, 2026

**CHEMCRUX ENTERPRISES LIMITED**  
**CONSOLIDATED STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2026**  
(Figures in Rs Lacs)

Sr.	Particulars	Year ended 31st March , 2026	Year ended 31st March , 2025
<b>A.</b>	<b>Cash flow from Operating Activities :</b>		
	<i>Net Profit before Tax &amp; Extra Ordinary Items</i>	528.22	576.54
	Adjustment for :		
	Depreciation & Write-offs	473.31	320.56
	Loss/(Profit) on Sale of PPE	-	(5.98)
	Provision For Expected Credit Loss	2.13	
	Interest Expense	314.68	174.55
	Interest Income	(9.61)	(74.67)
	Gain on Mutual Funds	(111.44)	(23.81)
	Gratuity Expense	13.92	14.20
	<b>Operating Profit before Working Capital Changes</b>	<b>1,211.21</b>	<b>981.39</b>
	Adjustments for :		
	(Increase)/Decrease in Trade Receivables	(672.30)	351.92
	(Increase)/Decrease in Inventories	390.99	(79.10)
	(Increase)/Decrease in Loans & Advances	3.47	(1.21)
	(Increase)/Decrease in other current assets	90.53	17.78
	Increase/(Decrease) in Trade Payable	453.27	(268.15)
	Increase/(Decrease) in Other Current Liabilities	46.56	(101.52)
	Increase/(Decrease) in Other Non Current Liabilities	(4.83)	-
	Increase/(Decrease) in Short term provisions	(2.00)	-
	<i>Cash Generated from Operating Activities</i>	<b>1,516.89</b>	<b>901.12</b>
	Direct Taxes Paid	(131.65)	(141.82)
	<i>Cash Flow before Extra Ordinary Items</i>	1,385.24	759.30
	Prior Period Items ( being cash items )	-	-
	<b>Net Cash Flow from Operating Activities</b>	<b>1,385.24</b>	<b>759.30</b>
<b>B.</b>	<b>Cash Flow from Investing Activities</b>		
	Purchase of PPE	(514.56)	(839.60)
	Net Proceeds from Sale of PPE	4.09	17.00
	Investments (Net)	500.00	149.48
	Interest Received	3.21	74.67
	<b>Net Cash used in Investment Activities</b>	<b>(7.25)</b>	<b>(598.46)</b>
<b>C.</b>	<b>Cash Flow from Financing Activities</b>		
	Interest Paid	(292.78)	(174.55)
	(Increase)/Decrease in Financial and Other - Non Current Assets	(2.01)	(41.43)
	Increase/(Decrease) in Short Term Borrowings	(134.23)	399.12
	Increase/(Decrease) in Lease Liabilities	(27.77)	(13.35)
	Increase/(Decrease) in Long Term Borrowings	(631.12)	(587.22)
	Dividend Paid	(148.09)	(148.09)
	<b>Net Cash used in Financing Activities</b>	<b>(1,236.00)</b>	<b>(565.52)</b>
<b>D.</b>	<b>Net Increase/(Decrease) in Cash and Bank Balance</b>	<b>141.98</b>	<b>(404.68)</b>
	Cash & Bank Balance at beginning of the year	114.52	518.24
	Cash & Bank Balance of Subsidiary on date of acquisition	-	0.97
	<b>Cash &amp; Bank balances at the end of the year</b>	<b>256.50</b>	<b>114.52</b>
	<b>Details of Cash &amp; Bank Balance</b>		
	Balances with Banks	240.43	99.75
	Cash on hand	3.53	2.23
	Deposits held as Margin Money	12.54	12.54
	Other Fixed Deposits with Bank	-	-


For & on behalf of the Board  
Chemcrux Enterprises Limited

  
Girishkumar Shah  
Whole Time Director  
DIN : 00469291



Place : Vadodara  
Date : 14th May, 2026

Regd. Office :-  
330, TRIVIA Complex, Natubhai Circle,  
Racecourse, Vadodara – 390007, Gujarat, INDIA  
Phone : +91 265 2988903 / 2984803  
Website : www.chemcrux.com  
Email : girishshah@chemcrux.com



14<sup>th</sup> May 2026

To  
BSE Limited  
Department of Corporate Services  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400 001

Dear Sir/Madam

**Subject:** Declaration in respect of unmodified opinion on Audited Consolidated Financial Statements & Results for the Financial Year ended 31<sup>st</sup> March 2026.

**Ref.:** BSE Scrip ID: **CHEMCRUX** BSE Scrip Code: **540395**

In terms of Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; I, Girishkumar Shah, Whole-time Director of Chemcrux Enterprises Limited, hereby declare that the Statutory Auditors of the Company viz. M/s Naresh & Co., Chartered Accountants (FRN 106928W); have issued Audit Report dated 14<sup>th</sup> May 2026 with unmodified opinion on the Annual Audited Consolidated Financial Statements & Results for the financial year ended 31<sup>st</sup> March 2026.

Kindly take the above on your records.

**For CHEMCRUX ENTERPRISES LIMITED**

A handwritten signature in blue ink, appearing to read "Girishkumar Shah".



**Girishkumar Shah**  
**Whole-time Director**